- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - ADCOCK INGRAM (S. Africa)
VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 VENUS REMEDIES  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-17 |
ADCOCK INGRAM Jun-14 |
VENUS REMEDIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 143 | 360 | - | |
| Low | Rs | 65 | 259 | - | |
| Sales per share (Unadj.) | Rs | 324.2 | 107.0 | - | |
| Earnings per share (Unadj.) | Rs | 6.4 | -27.0 | - | |
| Cash flow per share (Unadj.) | Rs | 40.6 | -22.3 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 366.0 | 84.0 | - | |
| Shares outstanding (eoy) | m | 12.34 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 2.9 | 11.1% | |
| Avg P/E ratio | x | 16.2 | -11.5 | -141.2% | |
| P/CF ratio (eoy) | x | 2.6 | -13.9 | -18.5% | |
| Price / Book Value ratio | x | 0.3 | 3.7 | 7.7% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,282 | 52,238 | 2.5% | |
| No. of employees | `000 | 0.9 | 4.3 | 21.0% | |
| Total wages/salary | Rs m | 251 | 3,279 | 7.7% | |
| Avg. sales/employee | Rs Th | 4,430.1 | 4,205.5 | 105.3% | |
| Avg. wages/employee | Rs Th | 278.0 | 763.7 | 36.4% | |
| Avg. net profit/employee | Rs Th | 87.6 | -1,059.7 | -8.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,000 | 18,054 | 22.2% | |
| Other income | Rs m | 23 | 126 | 18.0% | |
| Total revenues | Rs m | 4,023 | 18,181 | 22.1% | |
| Gross profit | Rs m | 785 | -3,129 | -25.1% | |
| Depreciation | Rs m | 422 | 779 | 54.1% | |
| Interest | Rs m | 344 | 489 | 70.3% | |
| Profit before tax | Rs m | 42 | -4,271 | -1.0% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | -37 | 267 | -13.9% | |
| Profit after tax | Rs m | 79 | -4,549 | -1.7% | |
| Gross profit margin | % | 19.6 | -17.3 | -113.2% | |
| Effective tax rate | % | -87.9 | -6.2 | 1,406.5% | |
| Net profit margin | % | 2.0 | -25.2 | -7.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,606 | 13,223 | 19.7% | |
| Current liabilities | Rs m | 1,980 | 7,440 | 26.6% | |
| Net working cap to sales | % | 15.6 | 32.0 | 48.8% | |
| Current ratio | x | 1.3 | 1.8 | 74.0% | |
| Inventory Days | Days | 128 | 111 | 115.7% | |
| Debtors Days | Days | 43 | 124 | 34.8% | |
| Net fixed assets | Rs m | 5,353 | 7,708 | 69.5% | |
| Share capital | Rs m | 123 | 84 | 147.2% | |
| Net worth | Rs m | 4,516 | 14,171 | 31.9% | |
| Long term debt | Rs m | 1,618 | 4,980 | 32.5% | |
| Total assets | Rs m | 8,291 | 26,770 | 31.0% | |
| Interest coverage | x | 1.1 | -7.7 | -14.5% | |
| Debt to equity ratio | x | 0.4 | 0.4 | 102.0% | |
| Sales to assets ratio | x | 0.5 | 0.7 | 71.5% | |
| Return on assets | % | 5.1 | -15.2 | -33.6% | |
| Return on equity | % | 1.8 | -32.1 | -5.5% | |
| Return on capital | % | 6.3 | -19.8 | -31.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 997 | 1,541 | 64.7% | |
| From Investments | Rs m | -461 | -473 | 97.5% | |
| From Financial Activity | Rs m | -571 | 4,520 | -12.6% | |
| Net Cashflow | Rs m | -35 | 5,587 | -0.6% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.96 Rs / ZAR
Compare VENUS REMEDIES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: PLETHICO PHARMA ABBOTT INDIA FULFORD INDIA ORCHID PHARMA LTD SUN PHARMA
|
| |
Today's Market
Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)
After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)
Jun 12, 2018 | Updated on Jun 12, 2018For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)
Jun 8, 2018The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.
Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)
Jun 13, 2018The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.
GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)
Jun 13, 2018Though it will bring transparency in their pricing and that in itself will be a welcome move.
Has the Market Bottomed Out?(Sector Info)
Jun 11, 2018The yield spread is an effective barometer that can indicate the direction the markets are headed.
Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)
Jun 8, 2018After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.
More|
| |
VENUS REMEDIES SHARE PRICE
Jun 20, 2018 (Close)
TRACK VENUS REMEDIES
- Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON VENUS REMEDIES
VENUS REMEDIES - ALEMBIC LTD COMPARISON
COMPARE VENUS REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.